NL-OMON46617CompletedPhase 2
A Pilot, Open-Label, Phase 2, Single-Center, Repeat Dose, Proof-of-Concept Safety, Pharmacodynamics and Efficacy Study of Orally Administered Dapansutrile Capsules in Subjects with Schnitzler*s Syndrome - Pilot Study of Dapansutrile in Schnitzler's Syndrome
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Olatec Therapeutics LLC
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1) Male and female subjects 18 years old or older
- •2) Prior diagnosis of Schnitzler*s syndrome
- •3) Presence of Schnitzler*s syndrome that is well controlled by and responsive to anakinra for at least 6 weeks prior to the Screening/Baseline visit
- •4) Grade 0 SchS symptoms at the Screening/Baseline visit
- •5) Acceptable overall medical condition to be safely enrolled in and to complete the study (with specific regard to cardiovascular, renal and hepatic conditions) in the opinion of the Investigator
- •6) Ability to provide written informed consent prior to initiation of any study-related procedures, and ability, in the opinion of the Investigator, to understand and comply with all the requirements of the study as outlined in the protocol.
Exclusion Criteria
- •1) Pregnant, nursing or intent to become pregnant during the study
- •2) Not responsive or well controlled by anakinra therapy for at least 3 months prior to the Screening/Baseline visit
- •3) Use or planned use of any prohibited concomitant medications/therapies such as immunotherapies or corticosteroids during the study (until relapse and resumption of anakinra injections)
- •4) Active infection within 3 days prior to the Screening/Baseline visit
- •5) History of or known positive for HIV, Hepatitis B surface antigen (HBsAg) or antibodies to Hepatitis C Virus (HCV)
- •6) Any other concomitant medical or psychiatric conditions, including alcohol or substance abuse, diseases or prior surgeries that in the opinion of the Investigator would impair the subject from safely participating in the trial and/or completing protocol requirements
- •7) Enrollment in any trial and/or use of any investigational product or device within the immediate 30-day period prior to the Screening/Baseline visit
- •8) Enrollment in any study previously sponsored by Olatec Therapeutics LLC, specifically Study OLT1177-01, Study OLT1177-02, Study OLT1177-03, Study OLT1177-04 or Study OLT1177-05
Investigators
Similar Trials
Active, not recruiting
Phase 1
Pilot Study of Dapansutrile Capsules in Schnitzler’s SyndromeSchnitzler's syndromeMedDRA version: 20.0Level: PTClassification code 10062908Term: Schnitzler's syndromeSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2017-003282-98-NLOlatec Therapeutics LLC10
Active, not recruiting
Phase 1
A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic andPharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged12 months through <24 monthsEUCTR2017-000407-24-Outside-EU/EEAHospira Inc6
Recruiting
Not Applicable
Gefitinib as Sequential Therapy in Stage III NSCL Patient With Sensitizing EGFR Mutations Who Have Not Progressed Following Platinum-based, CCRTNeoplasmsKCT0003376Asan Medical Center30
Active, not recruiting
Not Applicable
A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome - MEPOCHUSSChurg-Strauss-SyndromeMedDRA version: 9.1Level: LLTClassification code 10009164Term: Churg Strauss syndromeEUCTR2006-001791-20-DEniversity Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
Completed
Phase 1
Phase 1 study to evaluate the pharmacokinetics, safety, tolerability, and taste of tecovirimat pediatric formulationsISRCTN13846827Siga Technologies (United States)12